MedTrace Logo

Anesthesia Technique in COVID-19 Positive Hip Fracture Patients

NCT05133648 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-01-09

No results posted yet for this study

Summary

Patients with COVID undergoing hip fracture repair have high mortality rates. If spinal anesthesia is associated with decreased rates of mortality, this study could provide hypothesis generating data for prospective studies. Investigators hypothesize that spinal anesthesia (SA) is associated with decreased mortality compared to general anesthesia (GA) for patients undergoing hip fracture surgery. The primary objective is to determine for patients undergoing hip surgery with COVID-19 infection, whether SA, as compared to GA, is associated with a lower rate of mortality 30 days postoperatively. The secondary objective is to determine whether SA, as compared to GA, is associated with a lower rate of morbidity 30 days postoperatively. Investigators will be analyzing a data set provided by the National Surgical Quality Improvement Program (NSQIP). Descriptive statistics will be performed. Multivariable logistic regression will be performed for the primary and secondary objectives.

Conditions

  • Hip Fractures
  • COVID-19
  • General Anesthesia
  • Spinal Anesthesia

Interventions

PROCEDURE

Hip Fracture Surgery

Hip fracture surgery

OTHER

COVID-19 infection

COVID-19 infection

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Janny Xue Chen Ke, MD · University of British Columbia

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2023-12-01
Completion
2023-12-03

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05133648 on ClinicalTrials.gov